Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model

In this study, we investigated efficacy of lenalidomide in combination with tumor antigen-loaded dendritic cells (DCs) in murine colon cancer model. MC-38 cell lines were injected subcutaneously to establish colon cancer-bearing mice. After tumor growth, lenalidomide (50 mg/kg/day) was injected intraperitoneally on 3 consecutive days in combination with tumor antigen-loaded DC vaccination on days 8, 12, 16, and 20. The tumor antigen-loaded DCs plus lenalidomide combination treatment exhibited a significant inhibition of tumor growth compared with the other groups. These effects were associated with a reduction in immune suppressor cells, such as myeloid-derived suppressor cells and regulatory T cells, with the induction of immune effector cells, such as natural killer cells, CD4+ T cells and CD8+ T cells in spleen, and with the activation of cytotoxic T lymphocytes and NK cells. This study suggests that a combination of tumor antigen-loaded DC vaccination and lenalidomide synergistically enhanced antitumor immune response in the murine colon cancer model, by inhibiting the generation of immune suppressive cells and recovery of effector cells, and demonstrated superior polarization of Th1/Th2 balance in favor of Th1 immune response. This combination approach with DCs and lenalidomide may provide a new therapeutic option to improve the treatment of colon cancer.

[1]  Je-Jung Lee,et al.  Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma. , 2017, Experimental hematology.

[2]  K. Alam,et al.  A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model. , 2007, The Journal of surgical research.

[3]  Z. Estrov,et al.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. , 2008, Blood.

[4]  M. Caraglia,et al.  Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro1 , 2005, The Journal of Immunology.

[5]  N. Hayashi,et al.  Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2‐derived peptide‐pulsed dendritic cell vaccines , 2007, Cancer.

[6]  M. Czuczman,et al.  Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model , 2005, Clinical Cancer Research.

[7]  Je-Jung Lee,et al.  Sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells , 2016, Experimental & Molecular Medicine.

[8]  M. Czuczman,et al.  Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo , 2007, British journal of haematology.

[9]  J. Rhee,et al.  Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity , 2015, Oncotarget.

[10]  Je-Jung Lee,et al.  Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in a Model of Murine Multiple Myeloma , 2015, Journal of immunotherapy.

[11]  E. Gilboa,et al.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.

[12]  J. Whang‐Peng,et al.  Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA Peptides , 2004, Clinical Cancer Research.

[13]  J. Rhee,et al.  Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist , 2010, Experimental & Molecular Medicine.

[14]  Je-Jung Lee,et al.  Generation of potent dendritic cells with improved migration ability through p-cofilin and sarco/endoplasmic reticulum Ca(2+) transport ATPase 2 regulation. , 2015, Cytotherapy.

[15]  E. Van Cutsem,et al.  Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer , 2013, PloS one.

[16]  K. Shortman,et al.  Improving vaccines by targeting antigens to dendritic cells , 2009, Experimental & Molecular Medicine.

[17]  A. Dalgleish,et al.  The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells , 2009, Cancer Immunology, Immunotherapy.

[18]  M. Hanna,et al.  Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial , 1999, The Lancet.

[19]  Je-Jung Lee,et al.  Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro. , 2014, Experimental hematology.

[20]  I. Park,et al.  Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells , 2015, Journal of immunology research.

[21]  Je-Jung Lee,et al.  Generation of multiple peptide cocktail-pulsed dendritic cells as a cancer vaccine. , 2014, Methods in molecular biology.

[22]  Dr C. D. L. Reid.  Dendritic cells and immunotherapy for malignant disease , 2001, British journal of haematology.

[23]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[24]  A. Naing,et al.  Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer , 2016, Cancer Chemotherapy and Pharmacology.

[25]  Je-Jung Lee,et al.  Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic , 2015, Chonnam medical journal.

[26]  S. Burgdorf.  Dendritic cell vaccination of patients with metastatic colorectal cancer. , 2010, Danish medical bulletin.

[27]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[28]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[29]  A. Dalgleish,et al.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.

[30]  S. Kummar,et al.  Treatment of recurrent metastatic colon cancer in the age of modern adjuvant therapy. , 2008, Clinical colorectal cancer.